Advertisement
J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1194/jlr.M700213-JLR200 on August 13, 2007

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M700213-JLR200v1
48/11/2499    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chien, K.-L.
Right arrow Articles by Hu, F. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chien, K.-L.
Right arrow Articles by Hu, F. B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 48, 2499-2505, November 2007
Copyright © 2007 by American Society for Biochemistry and Molecular Biology

Patient-Oriented and Epidemiological Research

Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese

Kuo-Liong Chien1,*,{dagger},§, Hsiu-Ching Hsu{dagger}, Ta-Chen Su{dagger}, Ming-Fong Chen{dagger}, Yuan-Teh Lee1,{dagger},** and Frank B. Hu§

* Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
{dagger} Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
§ Department of Nutrition, School of Public Health, Harvard University, Boston, MA
** Ming-Shen Medical Center, Taoyuang, Taiwan

Published, JLR Papers in Press, August 13, 2007.

1 To whom correspondence should be addressed. e-mail: klchien{at}ha.mc.ntu.edu.tw (K-L.C.); ytlee{at}ha.mc.ntu.edu.tw (Y-T.L.)


ABSTRACT

The aim of our study was to compare apolipoprotein B (apoB), non-high density lipoprotein cholesterol (nonHDL-C), low density lipoprotein cholesterol (LDL-C), and other lipid markers as predictors of coronary heart disease (CHD) in Chinese. Overall, 122 individuals developed CHD during a median 13.6 years of follow-up in 3,568 adult participants from a community-based cohort. The multivariate relative risk of CHD in the highest quintile compared with the lowest quintile was 2.74 [95% confidence interval (CI), 1.45–5.19] for apoB, 1.98 (95% CI, 1.00–3.92) for nonHDL-C, and 1.86 (95% CI, 1.00–3.49) for LDL-C (all tests for trend, P < 0.05). ApoB also had the highest receiver operator characteristic curve area (0.63; 95% CI, 0.58–0.68) in predicting CHD. When apoB and nonHDL-C were mutually adjusted, only apoB was predictive; the relative risk was 2.80 (95% CI, 1.31–5.96; P = 0.001) compared with 1.09 (95% CI, 0.49–2.40; P = 0.75) for nonHDL-C. Compared with the lowest risk, participants with the highest apoB and total cholesterol/HDL-C had a 3-fold increased risk of developing CHD (relative risk = 3.21; 95% CI, 1.45–7.14). These data provide strong evidence that apoB concentration was a better predictor of CHD than other lipid markers in Chinese.

Supplementary key words lipids • lipoproteins • apolipoproteins • risk factors

Abbreviations: apoB, apolipoprotein B; CHD, coronary heart disease; LDL-C, low density lipoprotein cholesterol; nonHDL-C, non-high density lipoprotein cholesterol; ROC, receiver operator characteristic; TC, total cholesterol; TG, triglyceride

Increased low density lipoprotein cholesterol (LDL-C) concentrations are a well-established risk factor for coronary heart disease (CHD) and are currently recommended as the primary target for lipid-lowering therapy for the prevention and treatment of cardiovascular disease)(1). However, recent evidence suggests that apolipoproteins, especially apolipoprotein B (apoB), may be more strongly associated with CHD incidence than LDL (2, 3). Apolipoprotein plays a role in transporting lipid particles and is considered a direct measurement of proatherogenic particles (3, 4). In addition, non-high density lipoprotein cholesterol (nonHDL-C; calculated as the difference between total cholesterol and HDL cholesterol), reflecting the cholesterol concentration of all atherogenic lipoproteins, has also been demonstrated to predict CHD risk (5, 6). NonHDL-C has been recommended as a target for primary prevention among patients with diabetes or high triglyceride (TG) levels (1, 7). However, the superiority of LDL-C, apoB, and nonHDL-C in predicting CHD remains unsettled (8, 9). Furthermore, to our knowledge, no previous study has directly compared the predictive capacity of these biomarkers in Asian populations. Therefore, we conducted a prospective study to examine the role of apoB, nonHDL-C, and LDL-C in predicting CHD incidence among ethnic Chinese in Taiwan.


METHODS

Study design and study population
Details of this cohort study have been published previously (10–12). Briefly, the Chin-Shan Community Cardiovascular Cohort Study began in 1990 by recruiting 1,703 men and 1,899 women >=35 years old, homogeneous in Chinese ethnicity, and living in the Chin-Shan township 30 km north of metropolitan Taipei, Taiwan. Information about anthropometry, lifestyle, and medical conditions was assessed by interview questionnaires in 2 year cycles, and the validity and reproducibility of the collected data and measurements have been reported in detail elsewhere (12). In follow-up of the cohort through 2005 (median 13.6 years), we identified 122 incident cases of CHD (79 men, 43 women), defined as nonfatal myocardial infarction, fatal CHD, or hospitalization for percutaneous coronary intervention and coronary bypass surgery. Deaths were identified from official death certificates and further verified by house-to-house visits. Fatal CHD was considered to have occurred if there was fatal myocardial infarction confirmed by hospital records, or if CHD listed as the cause of death on the death certificate was the underlying and most plausible cause of death, or if evidence of previous CHD was available. The National Taiwan University Hospital Committee Review Board approved the study protocol. All participants provided oral informed consent when they were recruited into the study in 1990.

All venous blood samples drawn after a 12 h overnight fast were immediately refrigerated and transported within 6 h to National Taiwan University Hospital. Serum samples were then stored at –70°C before batch assay for levels of total cholesterol (TC), TG, HDL-C, apoA-I, and apoB. Standard enzymatic tests for serum cholesterol and TG were used (Merck 14354 and 14366, respectively). HDL-C levels were measured in supernatants after the precipitation of specimens with magnesium chloride phosphotungstate reagents (Merck 14993). LDL-C concentrations were calculated as TC minus cholesterol in the supernatant by the precipitation method (Merck 14992). ApoA-I and apoB concentrations were measured by turbidimetric immunoassay with commercial kits (Sigma). NonHDL-C was calculated by subtracting HDL-C from TC. A total of 3,568 participants with blood lipid data and free from cardiovascular disease at baseline were included in the study.

Statistical analysis
Participants were categorized on the basis of quintile of apoB levels, and continuous variables are presented by mean, standard deviation, or median levels; categorical data are presented in contingency tables, with ANOVA to test for differences among quintiles. Relationships between lipid marker levels were examined by the age- and gender-adjusted Spearman's partial correlation coefficients.

CHD incidence rates were calculated by person-year methods and stratified by various lipid marker quintiles. We analyzed the association between lipid levels and risk of CHD using the Cox regression model, adjusting for potential confounding factors. The proportionality assumption and the fit of the proportional hazards model were verified by the Grambsch and Therneau statistics (13). We specified two Cox models to evaluate the adjusted relative risks of quintile values. Model 1 was adjusted for age groups (35–44, 45–54, 55–64, 65–74, and >=75 years old) and gender only. Model 2 included additional confounding factors: body mass index (<18, 18–20.9, 21–22.9, 23–24.9, or >=25 kg/m2), smoking (yes/no or abstinence), current alcohol drinking (regular/no), marital status (single, married and living with spouse, or divorced and living separately), education level (<9 years, at least 9 years), occupation (no work, labor, office, or business), regular exercise habit (yes/no), family history of CHD (yes/no), baseline hypertension (yes/no, defined by blood pressure of at least 140/90 mm Hg or on medication), and diabetes mellitus (yes/no, defined by fasting plasma glucose of at least 126 mg/dl or on medication). To test for linear trends across lipid marker categories, we used the median lipid profile levels within quintiles as a continuous variable. We also tested the goodness of fit of the model using the Hosmer and Lemeshow test (14).

We used the area under the curve of the receiver operator characteristic (ROC curve) to compare the discriminative ability of various risk factors (15). The area under the ROC curve was considered a global performance indicator for a prognostic factor (16). In addition, likelihood ratio test statistics were used to compare model fitting. We compared models with and without the four dummy lipid profiles and conducted likelihood ratio tests between nested models.

All statistical tests were two-tailed, and P < 0.05 was considered statistically significant. Analyses were performed with SAS version 9.1 (SAS Institute, Cary, NC) and Stata version 9.1 (Stata Corp., College Station, TX).


RESULTS

Participants with higher apoB levels were more likely to be female and older. They were more likely to have higher body mass index, hypertension, diabetes mellitus, higher levels of TC, TG, LDL-C, nonHDL-C, TC/HDL-C, apoA-I, and apoB/apoA-I, and significantly lower levels of HDL-C. There were no statistical differences in lifestyle factors such as smoking, alcohol consumption, and exercise habits across various apoB quintiles (Table 1 ).


View this table:
[in this window]
[in a new window]

  		TABLE 1. Distribution of various baseline demographic, lifestyle, and socioeconomic factors in the study population in the CCCC (1990–1991), specified by apoB quintiles

 
We found strong correlations among TC, LDL-C, nonHDL-C, and TC/HDL-C, ranging from 0.76 to 0.98 (Table 2 ). HDL-C was inversely associated with other lipid markers, except with apoA-I (r = 0.62). The correlations of apoB with other lipid markers were moderate, ranging from 0.20 to 0.62.


View this table:
[in this window]
[in a new window]

  		TABLE 2. Age- and gender-adjusted Spearman partial correlation coefficients between various lipid profiles among the study subjects in the CCCC

 
Table 3 shows the relative risks of CHD during a median 13.6 years of follow-up across quintiles of lipid levels at baseline. After multivariate adjustment, the lipid ratios, such as TC/HDL-C and apoB/apoA-I, had the strongest associations with CHD (relative risks in the highest quintile = 3.04 and 2.61). Among single lipid markers, apoB showed the strongest association with CHD (relative risk = 2.74). NonHDL-C was also strongly predictive of CHD, with a multivariate risk similar to that of LDL (i.e., 1.98 vs. 1.86). The association of HDL-C with CHD was similar to that seen with LDL; participants in the lowest quintile had a 1.81-fold (1/0.55) higher risk of CHD than those in the highest quintile. Figure 1 shows the cumulative CHD event-free rates according to quintiles of apoB and nonHDL-C. Compared with those in the lower quintiles, participants with the highest apoB or nonHDL-C quintile had significantly lower CHD event-free rates.


View this table:
[in this window]
[in a new window]

  		TABLE 3. Relative risks (and 95% CI values) of CHD during a median 13.6 years of follow-up according to quintiles of baseline lipid profiles in 1990–1991 in the CCCC study

 

Figure 1
View larger version (17K):
[in this window]
[in a new window]

  		Fig. 1. Cumulative coronary heart disease (CHD) event-free rates according to quintiles of apolipoprotein B (apoB) (upper) and non-high density lipoprotein cholesterol (nonHDL-C) (lower).

 
To determine the predictive values of various lipid markers, we estimated the ROC curves and performed likelihood ratio tests. Except for lipid ratios (TC/HDL-C and apoB/apoA-I), both apoB and HDL-C showed greater ROC and likelihood ratio Chi-square values than TC, TG, LDL, or nonHDL-C (Table 4 ).


View this table:
[in this window]
[in a new window]

  		TABLE 4. Area under the ROC curve and likelihood ratio test of various lipid profiles for CHD among the study subjects in the CCCC (1990–2005)

 
In mutually adjusted models, apoB and apoB/apoA-I remained significant and strong risk factors for CHD, whereas other lipid variables became nonsignificant (Table 5 ). In joint analyses, participants in the highest tertile of both apoB and TC/HDL ratio had >3-fold greater risk of CHD than those in the lowest tertiles of both variables (Fig. 2 ).


View this table:
[in this window]
[in a new window]

  		TABLE 5. Combination of two lipid profiles adjusted for confounding factors in multivariable-adjusted models in the subjects

 

Figure 2
View larger version (17K):
[in this window]
[in a new window]

  		Fig. 2. Hazard risks of CHD during a median 13.6 years of follow-up according to tertiles of apoB and total cholesterol (TC)/HDL-C levels, adjusted for age, gender, body mass index, family history of CHD, diabetes, hypertension, alcohol intake, smoking, exercise habit, marital status, education, and job status. Cutoff points for tertiles of apoB were <77, 77–104, and >=104 mg/dl. Cutoff points for tertiles of TC/HDL-C were <3.62, 3.62–4.80, and >=4.80.

 

DISCUSSION

In this prospective cohort of middle-aged to older ethnic Chinese, higher levels of apoB were strongly and independently associated with increased future risk of CHD. ApoB appeared to be a stronger predictor of CHD risk than LDL or nonHDL-C. ApoB provided additional predictive power beyond the TC/HDL ratio.

Our results are consistent with previous studies conducted in primarily white populations (17). In the Health Professionals' Follow-Up Study conducted in the United States, apoB appeared to be the strongest predictor of CHD among individual lipid factors (17). After adjustment for matching factors, the relative risk of CHD in the highest quintile compared with the lowest quintile was 2.76 [95% confidence interval (CI), 1.66–4.58] for nonHDL-C, 3.01 (95% CI, 1.81–5.00) for apoB, and 1.81 (95% CI, 1.12–2.93) for LDL-C. As in our study, when apoB and nonHDL or LDL were mutually adjusted, only apoB remained statistically significant. Three other studies have also found strong and independent effects of apoB (18–20).

ApoB is synthesized by the liver, and because there is one apoB molecule in each lipoprotein particle, apoB reflects the total number of chylomicrons, VLDL, intermediate density lipoprotein, and LDL particles and can be viewed as total atherogenic burden (3). In our study, apoB was significantly related to CHD risk even after adjustment for other lipid markers, such as LDL-C and nonHDL-C values, despite its correlations with these markers.

Several studies have also suggested that nonHDL-C level is a better predictor of CHD than LDL-C level. In a sample of diabetic men, Jiang et al. (5) found that, after adjustment for age, body mass index, and other lifestyle risk factors, the multivariate relative risk of cardiovascular disease (the highest vs. the lowest quartile) was 2.34 (95% CI, 1.26–4.32) for nonHDL-C, 2.31 (95% CI, 1.23–4.35) for apoB, and 1.74 (95% CI, 0.99–3.06) for LDL cholesterol. The ROC areas were similar for apoB and nonHDL, and both were greater than for LDL-C. NonHDL-C has also been shown to be a strong predictor of cardiovascular disease risk in diabetic patients in two other studies. In the Strong Heart Study cohort, nonHDL-C was a stronger predictor of cardiovascular disease than LDL-C in 2,108 American Indian men and women aged 45–74 years with diabetes during an average of 9 years of follow-up (7). In a Finnish cohort study of 1,059 middle-aged men and women with type 2 diabetes, higher levels of nonHDL-C, as well as low HDL-C and TGs, were each independently associated with a 2-fold increased risk of CHD mortality during 7 years of follow-up (21). But these two studies did not compare the predictive values of apoB and nonHDL-C.

In our study, nonHDL-C was superior to LDL-C in predicting CHD risk, consistent with other studies (5, 22). Because nonHDL-C is easily calculated and highly correlated with apoB, it has been suggested that nonHDL-C can be substituted for apoB as a predictor of CHD risk (8, 23). However, our data showed that apoB was more strongly related to CHD risk than was nonHDL-C. Several subclinical disease studies provided evidence that apoB was superior to nonHDL-C in reflecting carotid and coronary artery atherosclerosis burden (24, 25). Our results support the hypothesis that direct measurement of the atherogenic particles (apoB concentration) is more biologically meaningful than the measurement of the cholesterol concentration in these particles (nonHDL-C concentration) (3, 17, 26). Neither nonHDL-C nor apoB measurements require fasting samples. In clinical practice, nonHDL-C is a simpler and more familiar approach to quantify all atherogenic lipoproteins. However, the methodology for measuring apoB has been standardized and is becoming more widely available (9).

To our knowledge, this is the first extensive investigation of various lipid markers and risk of CHD among ethnic Chinese. Evidence from other Asian populations also demonstrates that atherogenic particles play an important role in predicting CHD events, (27–31), but the head-to-head comparison of nonHDL-C and apoB has not been available. Because of the prospective cohort design, the baseline measurements of all cohort members were unlikely to be affected by storage and laboratory issues that might be raised in some nested case-control studies. The use of a community-based population could reduce the possibility of selection bias. We also included important socioeconomic status and lifestyle factors in the models to control for potential confounding factors. Finally, because few participants (<1%) reported taking cholesterol-lowering medications, our results were minimally affected by statins and other cholesterol-lowering drugs.

Our study had several potential limitations. First, the incident cases of CHD events were relatively few, even with a median 13.6 years of follow-up, which would reduce the power to detect subtle differences between various lipid markers and make the relative risk estimation unstable. However, the 95% CI values for the estimated relative risks were narrow and tests for linear trends were significant for most lipid variables. Second, because lipid levels were measured only once, our results might be attenuated by intraindividual variations.

In conclusion, we clearly demonstrate that apoB is more strongly associated than LDL-C with risk of CHD among ethnic Chinese. Our data indicate that apoB, a marker of LDL-carrying particles, should be taken into consideration in Asian populations, in addition to other lipid markers such as nonHDL-C. Because of only moderate correlation coefficients between apoB and other lipid markers (~0.2–0.6), we recommended that apoB be measured for comprehensive evaluation of CHD risk in Asian populations.


ACKNOWLEDGMENTS

The authors thank the participants in the Chin-Shan community and the cardiologists at National Taiwan University Hospital for their assistance in this study. This study was supported partly by grants from the National Science Council in Taiwan (Grants NSC 95-2314-B-002-125, NSC 94-2314-B-002-290, and NSC 94-2314-B-039-006). F.B.H.'s research is partly supported by an American Heart Association Established Investigator Award.

Manuscript received May 8, 2007 and in revised form July 5, 2007 and in re-revised form August 3, 2007.


REFERENCES

  1. Expert Panel. 2002. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 106: 3143–3421.

  2. Walldius, G., and I. Jungner. 2006. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence. J. Intern. Med. 259: 493–519.[CrossRef][Medline]

  3. Sacks, F. M. 2006. The apolipoprotein story. Atheroscler. Suppl. 7: 23–27.[Medline]

  4. Qureshi, A. I., W. H. Giles, J. B. Croft, L. R. Guterman, and L. N. Hopkins. 2002. Apolipoproteins A-1 and B and the likelihood of non-fatal stroke and myocardial infarction—data from the Third National Health and Nutrition Examination Survey. Med. Sci. Monit. 8: CR311–CR316.[Medline]

  5. Jiang, R., M. B. Schulze, T. Li, N. Rifai, M. J. Stampfer, E. B. Rimm, and F. B. Hu. 2004. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care. 27: 1991–1997.[Abstract/Free Full Text]

  6. Ridker, P. M., N. Rifai, N. R. Cook, G. Bradwin, and J. E. Buring. 2005. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. J. Am. Med. Assoc. 294: 326–333.[Abstract/Free Full Text]

  7. Lu, W., H. E. Resnick, K. A. Jablonski, K. L. Jones, A. K. Jain, W. J. Howard, D. C. Robbins, and B. V. Howard. 2003. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart Study. Diabetes Care. 26: 16–23.[Abstract/Free Full Text]

  8. Denke, M. A. 2005. Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation. 112: 3368–3370.[Free Full Text]

  9. Sniderman, A. D. 2005. Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is. Circulation. 112: 3366–3367.[Free Full Text]

  10. Chien, K. L., H. C. Hsu, F. C. Sung, T. C. Su, M. F. Chen, and Y. T. Lee. 2005. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: the Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis. 183: 147–155.[CrossRef][Medline]

  11. Chien, K. L., F. C. Sung, H. C. Hsu, T. C. Su, W. D. Chang, and Y. T. Lee. 2005. Relative importance of atherosclerotic risk factors for coronary heart disease in Taiwan. Eur. J. Cardiovasc. Prev. Rehabil. 12: 95–101.[CrossRef][Medline]

  12. Lee, Y. T., R. S. Lin, F. C. Sung, C. Y. Yang, K. L. Chien, W. J. Chen, T. C. Su, H. C. Hsu, and Y. C. Huang. 2000. Chin-Shan Community Cardiovascular Cohort in Taiwan: baseline data and five-year follow-up morbidity and mortality. J. Clin. Epidemiol. 53: 836–846.

  13. Grambsch, P. M., and T. M. Therneau. 1994. Proportional hazards test and diagnostics based on weighted residuals. Biometrika. 81: 515–526.[Abstract/Free Full Text]

  14. Hosmer, D. W., Jr., and S. Lemeshow. 2000. Applied Logistic Regression. 2nd edition. John Wiley & Sons, New York.

  15. Hanley, J. A., and B. J. McNeil. 1983. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 148: 839–843.[Abstract/Free Full Text]

  16. Greiner, M., D. Pfeiffer, and R. D. Smith. 2000. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev. Vet. Med. 45: 23–41.[CrossRef][Medline]

  17. Pischon, T., C. J. Girman, F. M. Sacks, N. Rifai, M. J. Stampfer, and E. B. Rimm. 2005. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. II. Circulation. 112: 3375–3383.[Abstract/Free Full Text]

  18. Lamarche, B., S. Moorjani, P. J. Lupien, B. Cantin, P. M. Bernard, G. R. Dagenais, and J. P. Despres. 1996. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation. 94: 273–278.[Abstract/Free Full Text]

  19. van Lennep, J. E., H. T. Westerveld, H. W. van Lennep, A. H. Zwinderman, D. W. Erkelens, and E. E. van der Wall. 2000. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler. Thromb. Vasc. Biol. 20: 2408–2413.[Abstract/Free Full Text]

  20. Walldius, G., I. Jungner, I. Holme, A. H. Aastveit, W. Kolar, and E. Steiner. 2001. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS Study): a prospective study. III. Lancet. 358: 2026–2033.[CrossRef][Medline]

  21. Lehto, S., T. Ronnemaa, S. M. Haffner, K. Pyorala, V. Kallio, and M. Laakso. 1997. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes. 46: 1354–1359.[Abstract]

  22. Cui, Y., R. S. Blumenthal, J. A. Flaws, M. K. Whiteman, P. Langenberg, P. S. Bachorik, and T. L. Bush. 2001. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch. Intern. Med. 161: 1413–1419.[Abstract/Free Full Text]

  23. Expert Panel. 2001. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J. Am. Med. Assoc. 285: 2486–2497.

  24. Keulen, E. T., M. Kruijshoop, N. C. Schaper, A. P. Hoeks, and T. W. de Bruin. 2002. Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B. Arterioscler. Thromb. Vasc. Biol. 22: 283–288.[Abstract/Free Full Text]

  25. Simon, A., G. Chironi, J. Gariepy, P. M. Del, and J. Levenson. 2005. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis. 179: 339–344.[CrossRef][Medline]

  26. Sniderman, A., K. Williams, S. Haffner, and N. Sattar. 2004. Insights from apoB: from better diagnosis and therapy to the Medusa hypothesis. Atheroscler. Suppl. 5: 19–24.[Medline]

  27. Bhalodkar, N. C., S. Blum, and E. A. Enas. 2006. Accuracy of the ratio of triglycerides to high-density lipoprotein cholesterol for predicting low-density lipoprotein cholesterol particle sizes, phenotype B, and particle concentrations among Asian Indians. Am. J. Cardiol. 97: 1007–1009.[CrossRef][Medline]

  28. Imke, C., B. L. Rodriguez, J. S. Grove, J. R. McNamara, C. Waslien, A. R. Katz, B. Willcox, K. Yano, and J. D. Curb. 2005. Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart Study. Arterioscler. Thromb. Vasc. Biol. 25: 1718–1722.[Abstract/Free Full Text]

  29. Curb, J. D., R. D. Abbott, B. L. Rodriguez, K. Masaki, J. Popper, R. Chen, H. Petrovitch, P. Blanchette, I. Schatz, and K. Yano. 2004. Prospective association between low and high total and low-density lipoprotein cholesterol and coronary heart disease in elderly men. J. Am. Geriatr. Soc. 52: 1975–1980.[CrossRef][Medline]

  30. Koba, S., T. Hirano, T. Sakaue, H. Takeuchi, M. Adachi, and T. Katagiri. 2002. An increased number of very-low-density lipoprotein particles is strongly associated with coronary heart disease in Japanese men, independently of intermediate-density lipoprotein or low-density lipoprotein. Coron. Artery Dis. 13: 255–262.[CrossRef][Medline]

  31. Wang, T. D., W. J. Chen, K. L. Chien, S. S. Seh-Yi Su, H. C. Hsu, M. F. Chen, C. S. Liau, and Y. T. Lee. 2001. Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population. Am. J. Cardiol. 88: 737–743.[CrossRef][Medline]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
G. Karthikeyan, K. K. Teo, S. Islam, M. J. McQueen, P. Pais, X. Wang, H. Sato, C. C. Lang, C. Sitthi-Amorn, M.R. Pandey, et al.
Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study.
J. Am. Coll. Cardiol., January 20, 2009; 53(3): 244 - 253.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. Williams, A. Tchernof, K. J. Hunt, L. E. Wagenknecht, S. M. Haffner, and A. D. Sniderman
Diabetes, Abdominal Adiposity, and Atherogenic Dyslipoproteinemia in Women Compared With Men
Diabetes, December 1, 2008; 57(12): 3289 - 3296.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation
J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1512 - 1524.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
Diabetes Care, April 1, 2008; 31(4): 811 - 822.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M700213-JLR200v1
48/11/2499    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chien, K.-L.
Right arrow Articles by Hu, F. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chien, K.-L.
Right arrow Articles by Hu, F. B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Advertisement
spacer
Advertisement
Advertisement